Co-Occurrence of Multiple Sclerosis & Ovarian Cancer: A Case Report and Literature Review

Fengxiang Han1, Caiwei Lu2, Chunxiang Luo1,3, Xiaohui Liao1,4, Donghua Xie1,5, Danni Xu6* and Yanda Lu6*

1Department of Gynaecology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
2Department of Rehabilitation Medicines, Hainan Medical University, Haikou, China
3Liaobu Township Community Health Service Center, Dongguan, Guangdong, China
4Gan Country District Dermatology Institute, Ganzhou, Jiangxi, China
5Xie Urology LLC, Margate, Florida, USA
6Department of Oncology, The First Affiliated Hospital of Hainan Medical University, Haikou, China

#Contributed equally

ABSTRACT

Background: The possibility of an association between Multiple Sclerosis (MS) and cancer has not been thoroughly investigated.

Case Presentation: We present a case of ovarian cancer in a 58-year-old woman with MS. Radical hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and pelvic and para-aortic lymph node dissection was performed. Pathohistological analysis and immunohistochemistry confirmed the diagnosis of a clear cell carcinoma of the left ovary, grade III, FIGO2014 stage IA. Adjuvant chemotherapy of paclitaxel-carboplatin regimen (paclitaxel 175mg/m2, carboplatin AUC 6, at intervals of 3 weeks) was implemented for 4 courses.

Conclusion: The occurrence of ovarian cancer in MS patients may be coincidental. Nevertheless, the long-term use of immunosuppressive and/or immunomodulatory drugs in MS and the incidence of cancer may be associated.

ARTICLE INFO

Article history:
Received: 11 December, 2020
Accepted: 2 January, 2021
Published: 27 January, 2021

Keywords:
Multiple sclerosis
ovarian cancer
incidence
risk factors
review
discussed. We present a case of co-occurrence of multiple sclerosis and ovarian cancer.

Case Presentation

This 58-year-old female patient of Han Chinese was diagnosed with MS and optic neuritis on the right eye in 2004 at age 43. The first manifestation of the disease was pain in the right eye and the paralysis of the right side of her body, dizziness. She was treated with a high dose of corticoids, interferon β and plasma exchange therapy. After such treatment for a month, her disease remained stable with no major signs of deterioration except for a temporary case of dysphasia. She was switched to prednisone 10 mg once a day for maintenance therapy which she had taken for nine years. For the past four years, she had taken laquinimod, an immunomodulator, in the dosage of 0.5 mg. She suffered from pain and visual impairment on her right eye in June 2017, diagnosed with a relapse of MS, optic neuritis. After high-dose corticoids pulse therapy, she was relieved and changed to low dose prednisone maintenance therapy. She maintained irregular outpatient follow-ups.

She had no smoking habit of tobacco and no family history of malignant tumors. In January 2019, she presented and was admitted to our hospital due to complaints of “abdominal distension for more than 3 months and progressive worsening.” Transvaginal colour Doppler ultra-sound detected a 172 mm×162mm×141 mm mixed cystic and solid pelvic mass with an irregular shape and little blood flow signals. An abdominal and pelvic magnetic resonance imaging (MRI) scan revealed an irregularly shaped cystic and solid mass in the pelvic measured approximately 170mm×160mm×140mm and a small proportion was solid. Enhanced MRI scanning demonstrated uneven enhancement of the solid part.

The serum cancer antigen 125 and 199 level were 58.40, 498.43 U/mL, respectively. At that time, a malignant tumor was suspected, possibly originating from the reproductive system. On the recto-vaginal and abdominal examinations, a huge cystic-solid mass in the pelvis and abdomen was non-adherence to the intestine and no involvement of sacroiliac ligament. Three gynaecologic oncology specialists and imaging specialists evaluated the MRI scan images and the findings of recto-vaginal and abdominal examinations. They considered that it would be helpful to more accurately identify the patient with early epithelial ovarian carcinoma that was likely to undergo optimal primary cytoreductive surgery.

On 19 January 2019, she underwent a hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and pelvic and para-aortic lymph node dissection. During the surgical operation, the peritoneal lavage cytology was negative. The surgical outcome was satisfactory, with no residual cancer foci. The postoperative biopsy results demonstrated a clear cell carcinoma, grade III, of the left ovary, which did not involve the right ovary, the uterus, the bilateral fallopian tubes and bilateral pelvic walls, with no lymph node involvement. The postoperative pathological stage was IA, according to the 2014 International Federation of Gynaecology and Obstetrics (FIGO) staging criteria for ovarian. Immunohistochemistry confirmed the diagnosis of a clear cell carcinoma (CK pan positive, Glypican positive, P53 positive, P16 positive, PAX-8 positive, and ER, PR, SALL4, CD30, CD117, WT-1 negative). Subsequently, adjuvant chemotherapy of paclitaxel-carboplatin regimen (paclitaxel 175mg/m2, carboplatin AUC 6, at intervals of 3 weeks) was implemented for 4 courses. At present, the patient continues to follow up closely.

Discussion

Ovarian cancer is rare in women under 40-year-old of age and most cancers in this age group are germ cell tumors. Above age 40, more than 90% are epithelial tumors and the risk increases with age, peaking in the late 70s [8]. Our patient was diagnosed with ovarian cancer at the age of 58, which is the expected age for this type of cancer.

Since ovarian cancer is insidious in presentation with few sentinel symptoms and lacks effective screening test strategies, most of the women present with late-stage disease [4]. Its clinical presentation often is that prodromal symptoms tend to be vague and include distension, constipation, and vague pelvic pressure. Pain is minimal, and the progression to advanced disease is insidious. Without sentinel symptoms of early disease, patients frequently present with symptoms at distant sites to the ovary [9]. Although the patient has a huge ovarian tumor, she has no symptoms such as pain, vaginal discharge, and only abdominal distension caused by increased pelvic pressure. This might be associated with MS and lack of regular follow-up.

The association of autoimmune diseases with cancer has been explored for several years, and reports have appeared suggesting an increased cancer risk in some autoimmune diseases [10, 11]. The long-term exposure of patients suffering from these disorders to immunosuppressive therapy may have confounded the association with cancer [12]. A nationwide population-based cohort study by Sun L M et al. in 2014 revealed that Taiwanese patients with MS have a higher risk of developing overall cancer types and breast cancer in particular [13]. However, earlier researchers also found that MS patients were not at a higher risk of developing cancer overall or were even at a low risk than the general popular [14-16]. The researchers believed that the pathogenic mechanisms involved in MS are associated with the autoimmune response of autoreactive T cells against myelin peptides. As MS is a chronic autoimmune disease, the immunogenic process that leads to persistent immune stimulation may inhibit carcinogenesis [17].

Marrie R A et al. conducted a meta-analysis for population-based studies. 38 studies evaluated the incidence or prevalence of MS. They found that cervical, breast, and digestive cancers had the highest incidence. The risk of meningiomas and urinary system cancers appeared higher than expected, while the risks of pancreatic, ovarian, prostate and testicular cancers were lower than expected. They believed that the complexity of understanding cancer risk in MS is augmented by inconsistencies in study design and the relative paucity of age, sex and ethnicity-specific risk estimates from which the strong impact of age on the incidence of cancers can be assessed [18].

Our patient used a high dose of corticoids, interferon β in acute attacks in the initial stages of the disease, and she later had used prednisone for maintenance therapy for nine years, then laquinimod for four years. When she relapsed into MS two years ago, she was changed to corticoids maintenance therapy after relief by corticoids pulse therapy. Laquinimod
has been turned down two times by the European Medicines Agency’s Committee for Medicinal Products for Human Use because of concerns about possible teratogenic effects and cancer in animal studies of long-term exposure to laquinimod. The latest research, however, showed that there was no increase in the incidence of malignancies in long term use of laquinimod [19].

The patient has a huge ovarian tumor in the pelvis, but the postoperative pathological stage was IA which is in the earlier stages. We speculate that the reason may be related to the pathological type of clear cells. Clear cell carcinomas account for 10% of epithelial ovarian cancers and are similar to endometrioid cancers in that they have a relatively good prognosis. This is because they, too, are often diagnosed in the earlier stages. If diagnosed late or once the disease has advanced, the prognosis will be similar to that of the serous or endometrioid type. This is partial because of the cells being less sensitive to platinum-based chemotherapy, as well as associated complications that are seen with this diagnosis (i.e., blood clots and paraneoplastic hypercalcemia) [20]. Because mortality is closely related to disease stage at diagnosis (the 5 year survival rate is higher than 70% in stage I or II, but decreases to 40 and 20% in stages III and IV, respectively), an early diagnosis and timely surgical and/or chemotherapeutic treatment are vital [21].

It is estimated that approximately 18% of epithelial ovarian cancers, particularly high-grade serous carcinomas, are caused by inherited mutations that confer elevated risk, the majority in the BRCA1 or BRCA2 gene. Mutations in BRCA1 and BRCA2 account for almost 40% of ovarian cancer cases in women with a family history of the disease [22]. Holzmann C et al. reported a case of ac.5266dupc (5382insC) frameshift mutation in 33-year-old woman with breast cancer, multiple malignant melanomas and MS, whose family shows further cases of MS in BRCA1 mutation carriers [23]. To our patient, except for ovarian cancer, she had no personal and family history of malignant tumors. Although BRCA1/2 mutation tests were not carried out, it was unlikely that she had BRCA1/2 mutation.

Conclusion

Patients with MS may require additional attention due to the effect of their therapy and lack of symptoms when ovarian cancers are considered. An early diagnosis and timely surgical and/or chemotherapeutic treatment are vital.

Acknowledgement

None.

Authors Contributions

DX (Xu) and YL conceptualized and designed the study; FH, CL (Luo), XL and CL (Lu) collected the data; XL, CL (Luo), DX (Xie), FH, DX (Xu) and YL wrote the manuscript; All authors contributed to data interpretation, read the final manuscript and gave the approval.

Funding

None.

Availability of Data and Materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for Publication

Written informed consent was obtained from the patients for publication of this report and any accompanying images, according to the principles of the Declaration of Helsinki (Link). Copies of the written consent are available for review by the editor of the journal.

Ethics Approval and Consent to Participate

Ethical and regulatory approvals were sought and obtained from the First Affiliated Hospital of Hainan Medical University.

Competing Interests

None.

Abbreviations

MS: Multiple Sclerosis
CNS: Central Nervous System
MRI: Magnetic Resonance Imaging
FIGO: Federation of Gynaecology and Obstetrics
CK: Cytokeratin
PAX8: Paired-box gene 8
ER: Estrogen Receptor
PR: Progesterone Receptor
SALL4: Spalt Like Transcription Factor 4
CD: Cluster of Differentiation
WT: Wilms Tumor Protein
AUC: Area Under the Plasma Concentration/Time Curve
BRCA: Breast Cancer Gene

REFERENCES

1. Jemal A, Siegel R, Ward E, HaoY, Xu J et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96. [Crossref]
2. Yang N, Yan Q, Zheng R (2013) An analysis of incidence and mortality for ovarian cancer in China, 2009. China Cancer 22: 617-621.
3. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67: 7-30. [Crossref]
4. Gupta KK, Gupta VK, Naumann RW (2019) Ovarian cancer: screening and future directions. Int J Gynecol Cancer 29: 195-200. [Crossref]
5. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinschenker BG (2000) Multiple sclerosis. N Engl J Med 343: 938-952. [Crossref]
6. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359: 1221-1231. [Crossref]
7. Kyritsis AP, Boussios S, Pavlidis N (2016) Cancer specific risk in multiple sclerosis patients. Crit Rev Oncol Hematol 98: 29-34. [Crossref]
8. Webb PM, Jordan SJ (2017) Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 41: 3-14. [Crossref]
9. Goff B (2012) Symptoms associated with ovarian cancer. Clin Obstet Gynecol 55: 36-42. [Crossref]
10. Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K (2012) Autoimmune disease and subsequent digestive tract cancer by histology. Ann Oncol 23: 927-933. [Crossref]
11. Landgren AM, Landgren O, Gridly G, Dores GM, Linet MS et al. (2011) Autoimmune disease and subsequent risk of developing alimentary tract cancer among 4.5 million US male veterans. Cancer 117: 1163-1171. [Crossref]
12. Achiron A, Barak Y, Gail M, Mandel M, Pee D et al. (2005) Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat 89: 265-270. [Crossref]
13. Sun LM, Lin CL, Chung CJ, Liang JA, Sung FC et al. (2014) Increased breast cancer risk for patients with multiple sclerosis: A nationwide population-based cohort study. Eur J Neurol 21: 283-244. [Crossref]
14. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ (2010) Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson’s disease: record linkage studies. J Neurol Neurosurg Psychiatry 81: 215-221. [Crossref]
15. Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J et al. (2012) Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain 135: 2973-2979. [Crossref]
16. Handel AE, Ramagopalan SV (2010) Multiple sclerosis and risk of cancer: a meta-analysis. J Neurol Neurosurg Psychiatry 81: 1413-1414. [Crossref]
17. Cohen IR (2000) Discrimination and dialogue in the immune system. Semin Immunol 12: 215-219. [Crossref]
18. Marrie RA, Reider N, Cohen J, Stuve O, Trojano M et al. (2015) A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Mult Scler 21: 294-304. [Crossref]
19. Kolb Sobieraj C, Gupta S, Weinstock Guttman B (2014) Laquinimod therapy in multiple sclerosis: a comprehensive review. Neurol Ther 3: 29-39. [Crossref]
20. Stewart C, Ralyea C, Lockwood S (2019) Ovarian cancer: An integrated review. Semin Oncol Nurs 35: 151-156. [Crossref]
21. Xu Y, Zhong R, He J, Ding R, Lin H et al. (2016) Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China. Clin Biochem 49: 32-40. [Crossref]
22. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G et al. (2018) Ovarian Cancer Statistics, 2018. CA Cancer J Clin 68: 284-296. [Crossref]
23. Holzmann C, Bauer I, Meyer P (2013) Co-occurrence of multiple sclerosis and cancer in a BRCA1 positive family. Eur J Med Genet 6: 577-579. [Crossref]